Commercial Supply Services

We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial challenged environment. mAbxience currently has 2 biosimilars in different markets worldwide, bevacizumab and rituximab; and is presently working on a very attractive pipeline.